Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25429921 | 0.86 | CHEK1 (0.63) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL2977108 | 0.79 | EGFR (0.45) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL31691580 | 0.78 | CHEK1 (0.49) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL28048800 | 0.77 | CHEK1 (0.42) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL3638105 | 0.77 | CHEK1 (0.47) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL952561 | 0.77 | CHEK1 (0.47) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL878217 | 0.77 | CHEK1 (0.73) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL27810215 | 0.75 | CHEK1 (0.40) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL13726686 | 0.75 | CYP2A6 (0.46) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL29569628 | 0.75 | CYP2A6 (0.54) | CLK4DYRK1BCYP2A6MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230053726-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-02-23 | — | — | US | disclosed |
| US-11034682-B2 | Gamma-diketones as wnt/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200223834-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | MED-PATHWAYS II LIMITED (VG) | 2020-07-16 | — | — | US | disclosed |
| US-10457672-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2019-10-29 | — | — | US | disclosed |
| EP-3456325-A2 | GAMMA-DIKETONES AS WNT/BETA-CATENIN SIGNALLING PATHWAY ACTIVATORS | Samumed, LLC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20190055227-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2019-02-21 | — | — | US | disclosed |
| US-9951053-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170260176-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | MED-PATHWAYS II LIMITED (VG) | 2017-09-14 | — | — | US | disclosed |
| US-9533976-B2 | γ-diketones as WNT/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| EP-2968249-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | Samumed, LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20140243349-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2014-08-28 | — | — | US | disclosed |
| WO-2014130869-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | SAMUMED, LLC (US) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223834-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | CHEK1 783/4885AURKA 424/4885DAPK3 54/4885 |
| US-20190055227-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | CHEK1 783/4885AURKA 424/4885DAPK3 54/4885 |
| US-20170260176-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | CHEK1 783/4885AURKA 424/4885DAPK3 54/4885 |
| US-10457672-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | CHEK1 827/4885AURKA 434/4885DAPK3 43/4885 |
| US-20230053726-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | CHEK1 783/4885AURKA 424/4885DAPK3 54/4885 |
| US-11034682-B2 | Gamma-diketones as wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | CHEK1 790/4885AURKA 407/4885DAPK3 59/4885 |
| US-20140243349-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | CHEK1 783/4885AURKA 424/4885DAPK3 54/4885 |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | CHEK1 827/4885AURKA 434/4885DAPK3 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.